An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations User montaukwhaler, in the non small cell lung cancer subreddit, 17 Jul 2021